Technical Analysis for CYCN - Cyclerion Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 13.63 -1.94% -0.27
CYCN closed down 1.94 percent on Wednesday, September 18, 2019, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical CYCN trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Expansion Breakout Bullish Swing Setup -1.94%
Pocket Pivot Bullish Swing Setup -1.94%
Upper Bollinger Band Walk Strength -1.94%
Wide Bands Range Expansion -1.94%
Above Upper BB Strength -1.94%
Overbought Stochastic Strength -1.94%

Older signals for CYCN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.
Medicine Biopharmaceutical Medical Specialties Diseases Organ Systems Heart Failure Kidney Diseases Diabetic Nephropathy Sickle Cell Disease Cardiomyopathy
Is CYCN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.0
52 Week Low 7.83
Average Volume 103,233
200-Day Moving Average 0.0
50-Day Moving Average 10.1888
20-Day Moving Average 10.363
10-Day Moving Average 11.389
Average True Range 1.0546
ADX 41.99
+DI 38.1401
-DI 5.7745
Chandelier Exit (Long, 3 ATRs ) 11.3362
Chandelier Exit (Short, 3 ATRs ) 11.443799999999999
Upper Bollinger Band 13.2179
Lower Bollinger Band 7.5081
Percent B (%b) 1.07
BandWidth 55.097945
MACD Line 0.8536
MACD Signal Line 0.3878
MACD Histogram 0.4658
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.10
Resistance 3 (R3) 15.23 14.86 14.86
Resistance 2 (R2) 14.86 14.49 14.80 14.77
Resistance 1 (R1) 14.25 14.26 14.07 14.12 14.69
Pivot Point 13.88 13.88 13.79 13.82 13.88
Support 1 (S1) 13.27 13.51 13.09 13.14 12.57
Support 2 (S2) 12.90 13.28 12.84 12.49
Support 3 (S3) 12.29 12.90 12.41
Support 4 (S4) 12.16